Search results for barclays

Stocks | dougherty responds failure interdigitals idcc strategic review produce sale downgrading shares neutral suitor way interdigital contend unresolved patent dispute nokia market share losses i ii licensees research motion htc however barclays sees interdigitals q results reason hope All

Stocks | Ockham Research submits:

Shares of Celgene (CELG) are off more than 15% since issuing profit warning Wednesday morning. They are primarily involved in the treatment of cancer and immune-inflammatory diseases and judging by sales growth in the last few years some of their therapies have started to gain traction. The company says that they expect revenue to be around $600 million in quarter versus estimates of $647.1 million. Furthermore the company guided EPS $2.05 to $2.15 for the full year on the low end of the prior range and well below the expected EPS of $2.17.

"We’ve got Apollo education company falling and Celgene at a 52-week low. The company being downgraded left and right. Citigroup Barclays Lazard’s the list goes on and on the and the company fell short of expectations." Fox Business Network Wednesday

Complete Story » All

Stocks | barclays crushed All